Global Dysautonomia Market

Dysautonomia Comprehensive Study by Type (Neurocardiogenic Syncope, Postural Orthostatic Tachycardia Syndrome, Multiple System Atrophy, Autonomic Dysreflexia, Baroreflex Failure, Others), Treatment (Physical Therapy, Exercise Therapy, Counseling, Others), Tests (Cardiovagal and Vasomotor Function Tests, Thermoregulatory Sweat Test (TST), Sympathetic Skin Response (SSR), Quantitative Sudomotor Axon Reflex Test, Others) Players and Region - Global Market Outlook to 2028

Dysautonomia Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Dysautonomia
Dysautonomia is a disorder of autonomic nervous system (ANS) function which generally involves the failure of sympathetic components of the ANS, it also involves excessive or overactive ANS. It occurs as a primary condition or with degenerative neurological diseases like Parkinson's disease various other generalized primary dysautonomia includes multiple system atrophy and family history dysautonomia. Several common conditions such as diabetes and alcoholism can include also include dysautonomia. Right now there is no cure for dysautonomia, its secondary forms might improve with the therapy of an underlying disease. Methods to treat or combat with hypotension include elevation of the head of the bed, water bolus, high salt diet and drugs such as fludrocortisone and midodrine.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


Individuals living with dysautonomia face a complex landscape of medical professionals, research institutions, and support groups. It's crucial to build a strong team of healthcare providers who understand dysautonomia and can work together to develop a personalized treatment plan. Joining patient support groups and online communities can also provide valuable information, connection, and emotional support. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novartis Pharmaceuticals Corporation (Switzerland), Corlanor (Amgen Inc.) (United States), NORTHERA (Lundbeck NA Ltd.) (United States), Teva Cares Foundation (Teva Pharmaceutical Industries, Ltd) (United States), Pfizer Inc. (United States), Celltex Therapeutics Corporation (United States), Merck Sharp & Dohme Corp. (United States), Theravance Biopharma (United States), Shire Development, Inc. (United States) and H. Lundbeck A/S (Denmark) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Axsome Therapeutics, Inc. (United States), Medtronic (Dublin, Ireland), Biotronik (Germany), Nfocus Neuro (United States) and Cala Health (United States).

Segmentation Overview
AMA Research has segmented the market of Global Dysautonomia market by Type (Neurocardiogenic Syncope, Postural Orthostatic Tachycardia Syndrome, Multiple System Atrophy, Autonomic Dysreflexia, Baroreflex Failure and Others) and Region.



On the basis of geography, the market of Dysautonomia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Physical Therapy will boost the Dysautonomia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Tests, the sub-segment i.e. Cardiovagal and Vasomotor Function Tests will boost the Dysautonomia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Exercises and Counseling Related Treatment for Dysautonomia and Prevalence of Neurocardiogenic Syncope and Postural Orthostatic Tachycardia Syndrome forms of Dysautonomia

Market Growth Drivers:
Increasing Prevalence of Diabetic and Degenerative Neurological Diseases and Rising Number of Problems with Peripheral Nerves

Challenges:
Stiff Competition Among Players

Restraints:
Regulatory Compliance Regarding Dysautonomia and Expensive Dysautonomia Treatment Therapies

Opportunities:
Continuous Research and Development in the Drugs and Treatment for Dysautonomia

Market Leaders and their expansionary development strategies
In October 2023, BioXcel Therapeutics and Dysautonomia International partner to develop a novel dysautonomia treatment this collaboration focuses on bringing BioXcel's drug candidate, BXCL501, through clinical trials for the treatment of postural orthostatic hypotension (POTS), a common symptom of dysautonomia.
In September 2023, NIH funds research on wearable sensor and AI system for postural tachycardia syndrome (POTS) this project aims to develop a system that continuously monitors vital signs and uses AI to predict and prevent POTS symptoms, a common form of dysautonomia.
"Numerous automated ANS testing devices have been cleared for marketing by the U.S. Food and Drug Administration through the 510k process (e.g., QHRV System, VitalScan, ANSAR ANX, ZYTO Scan Hand Cradle, Neuropad, Sudoscan, EZScan, Natus VikingQuest, Bodytronic 200). These devices, along with newer methodologies (e.g., quantitative direct and indirect testing of sudomotor function [QDIRT]) propose to generate data after approximately 10-15 minutes of testing and without physician interpretation. According to the American Academy of Neurology, these methods and/or devices have insufficient published literature to establish clinical utility. Many devices are severely limited in the validity of the data they generate because they do not measure or control for expiratory pressure or include beat-to-beat blood pressure measurement, both of which are requirements, not only for scientifically accurate assessment but also for billing of autonomic testing."

Key Target Audience
Dysautonomia Testing Devices Manufacturers, Dysautonomia Treatment Association and Institutes, Regulatory Bodies, Dysautonomia Drugs and Testing Equipment Investors and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Neurocardiogenic Syncope
  • Postural Orthostatic Tachycardia Syndrome
  • Multiple System Atrophy
  • Autonomic Dysreflexia
  • Baroreflex Failure
  • Others
By Treatment
  • Physical Therapy
  • Exercise Therapy
  • Counseling
  • Others

By Tests
  • Cardiovagal and Vasomotor Function Tests
  • Thermoregulatory Sweat Test (TST)
  • Sympathetic Skin Response (SSR)
  • Quantitative Sudomotor Axon Reflex Test
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Diabetic and Degenerative Neurological Diseases
      • 3.2.2. Rising Number of Problems with Peripheral Nerves
    • 3.3. Market Challenges
      • 3.3.1. Stiff Competition Among Players
    • 3.4. Market Trends
      • 3.4.1. Increasing Exercises and Counseling Related Treatment for Dysautonomia
      • 3.4.2. Prevalence of Neurocardiogenic Syncope and Postural Orthostatic Tachycardia Syndrome forms of Dysautonomia
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dysautonomia, by Type, Treatment, Tests and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Dysautonomia (Value)
      • 5.2.1. Global Dysautonomia by: Type (Value)
        • 5.2.1.1. Neurocardiogenic Syncope
        • 5.2.1.2. Postural Orthostatic Tachycardia Syndrome
        • 5.2.1.3. Multiple System Atrophy
        • 5.2.1.4. Autonomic Dysreflexia
        • 5.2.1.5. Baroreflex Failure
        • 5.2.1.6. Others
      • 5.2.2. Global Dysautonomia by: Treatment (Value)
        • 5.2.2.1. Physical Therapy
        • 5.2.2.2. Exercise Therapy
        • 5.2.2.3. Counseling
        • 5.2.2.4. Others
      • 5.2.3. Global Dysautonomia by: Tests (Value)
        • 5.2.3.1. Cardiovagal and Vasomotor Function Tests
        • 5.2.3.2. Thermoregulatory Sweat Test (TST)
        • 5.2.3.3. Sympathetic Skin Response (SSR)
        • 5.2.3.4. Quantitative Sudomotor Axon Reflex Test
        • 5.2.3.5. Others
      • 5.2.4. Global Dysautonomia Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Dysautonomia: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis Pharmaceuticals Corporation (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Corlanor (Amgen Inc.) (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. NORTHERA (Lundbeck NA Ltd.) (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Cares Foundation (Teva Pharmaceutical Industries, Ltd) (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Celltex Therapeutics Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck Sharp & Dohme Corp. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Theravance Biopharma (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shire Development, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. H. Lundbeck A/S (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Dysautonomia Sale, by Type, Treatment, Tests and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Dysautonomia (Value)
      • 7.2.1. Global Dysautonomia by: Type (Value)
        • 7.2.1.1. Neurocardiogenic Syncope
        • 7.2.1.2. Postural Orthostatic Tachycardia Syndrome
        • 7.2.1.3. Multiple System Atrophy
        • 7.2.1.4. Autonomic Dysreflexia
        • 7.2.1.5. Baroreflex Failure
        • 7.2.1.6. Others
      • 7.2.2. Global Dysautonomia by: Treatment (Value)
        • 7.2.2.1. Physical Therapy
        • 7.2.2.2. Exercise Therapy
        • 7.2.2.3. Counseling
        • 7.2.2.4. Others
      • 7.2.3. Global Dysautonomia by: Tests (Value)
        • 7.2.3.1. Cardiovagal and Vasomotor Function Tests
        • 7.2.3.2. Thermoregulatory Sweat Test (TST)
        • 7.2.3.3. Sympathetic Skin Response (SSR)
        • 7.2.3.4. Quantitative Sudomotor Axon Reflex Test
        • 7.2.3.5. Others
      • 7.2.4. Global Dysautonomia Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dysautonomia: by Type(USD Million)
  • Table 2. Dysautonomia Neurocardiogenic Syncope , by Region USD Million (2017-2022)
  • Table 3. Dysautonomia Postural Orthostatic Tachycardia Syndrome , by Region USD Million (2017-2022)
  • Table 4. Dysautonomia Multiple System Atrophy , by Region USD Million (2017-2022)
  • Table 5. Dysautonomia Autonomic Dysreflexia , by Region USD Million (2017-2022)
  • Table 6. Dysautonomia Baroreflex Failure , by Region USD Million (2017-2022)
  • Table 7. Dysautonomia Others , by Region USD Million (2017-2022)
  • Table 8. Dysautonomia: by Treatment(USD Million)
  • Table 9. Dysautonomia Physical Therapy , by Region USD Million (2017-2022)
  • Table 10. Dysautonomia Exercise Therapy , by Region USD Million (2017-2022)
  • Table 11. Dysautonomia Counseling , by Region USD Million (2017-2022)
  • Table 12. Dysautonomia Others , by Region USD Million (2017-2022)
  • Table 13. Dysautonomia: by Tests(USD Million)
  • Table 14. Dysautonomia Cardiovagal and Vasomotor Function Tests , by Region USD Million (2017-2022)
  • Table 15. Dysautonomia Thermoregulatory Sweat Test (TST) , by Region USD Million (2017-2022)
  • Table 16. Dysautonomia Sympathetic Skin Response (SSR) , by Region USD Million (2017-2022)
  • Table 17. Dysautonomia Quantitative Sudomotor Axon Reflex Test , by Region USD Million (2017-2022)
  • Table 18. Dysautonomia Others , by Region USD Million (2017-2022)
  • Table 19. South America Dysautonomia, by Country USD Million (2017-2022)
  • Table 20. South America Dysautonomia, by Type USD Million (2017-2022)
  • Table 21. South America Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 22. South America Dysautonomia, by Tests USD Million (2017-2022)
  • Table 23. Brazil Dysautonomia, by Type USD Million (2017-2022)
  • Table 24. Brazil Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 25. Brazil Dysautonomia, by Tests USD Million (2017-2022)
  • Table 26. Argentina Dysautonomia, by Type USD Million (2017-2022)
  • Table 27. Argentina Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 28. Argentina Dysautonomia, by Tests USD Million (2017-2022)
  • Table 29. Rest of South America Dysautonomia, by Type USD Million (2017-2022)
  • Table 30. Rest of South America Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 31. Rest of South America Dysautonomia, by Tests USD Million (2017-2022)
  • Table 32. Asia Pacific Dysautonomia, by Country USD Million (2017-2022)
  • Table 33. Asia Pacific Dysautonomia, by Type USD Million (2017-2022)
  • Table 34. Asia Pacific Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 35. Asia Pacific Dysautonomia, by Tests USD Million (2017-2022)
  • Table 36. China Dysautonomia, by Type USD Million (2017-2022)
  • Table 37. China Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 38. China Dysautonomia, by Tests USD Million (2017-2022)
  • Table 39. Japan Dysautonomia, by Type USD Million (2017-2022)
  • Table 40. Japan Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 41. Japan Dysautonomia, by Tests USD Million (2017-2022)
  • Table 42. India Dysautonomia, by Type USD Million (2017-2022)
  • Table 43. India Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 44. India Dysautonomia, by Tests USD Million (2017-2022)
  • Table 45. South Korea Dysautonomia, by Type USD Million (2017-2022)
  • Table 46. South Korea Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 47. South Korea Dysautonomia, by Tests USD Million (2017-2022)
  • Table 48. Taiwan Dysautonomia, by Type USD Million (2017-2022)
  • Table 49. Taiwan Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 50. Taiwan Dysautonomia, by Tests USD Million (2017-2022)
  • Table 51. Australia Dysautonomia, by Type USD Million (2017-2022)
  • Table 52. Australia Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 53. Australia Dysautonomia, by Tests USD Million (2017-2022)
  • Table 54. Rest of Asia-Pacific Dysautonomia, by Type USD Million (2017-2022)
  • Table 55. Rest of Asia-Pacific Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 56. Rest of Asia-Pacific Dysautonomia, by Tests USD Million (2017-2022)
  • Table 57. Europe Dysautonomia, by Country USD Million (2017-2022)
  • Table 58. Europe Dysautonomia, by Type USD Million (2017-2022)
  • Table 59. Europe Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 60. Europe Dysautonomia, by Tests USD Million (2017-2022)
  • Table 61. Germany Dysautonomia, by Type USD Million (2017-2022)
  • Table 62. Germany Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 63. Germany Dysautonomia, by Tests USD Million (2017-2022)
  • Table 64. France Dysautonomia, by Type USD Million (2017-2022)
  • Table 65. France Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 66. France Dysautonomia, by Tests USD Million (2017-2022)
  • Table 67. Italy Dysautonomia, by Type USD Million (2017-2022)
  • Table 68. Italy Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 69. Italy Dysautonomia, by Tests USD Million (2017-2022)
  • Table 70. United Kingdom Dysautonomia, by Type USD Million (2017-2022)
  • Table 71. United Kingdom Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 72. United Kingdom Dysautonomia, by Tests USD Million (2017-2022)
  • Table 73. Netherlands Dysautonomia, by Type USD Million (2017-2022)
  • Table 74. Netherlands Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 75. Netherlands Dysautonomia, by Tests USD Million (2017-2022)
  • Table 76. Rest of Europe Dysautonomia, by Type USD Million (2017-2022)
  • Table 77. Rest of Europe Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 78. Rest of Europe Dysautonomia, by Tests USD Million (2017-2022)
  • Table 79. MEA Dysautonomia, by Country USD Million (2017-2022)
  • Table 80. MEA Dysautonomia, by Type USD Million (2017-2022)
  • Table 81. MEA Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 82. MEA Dysautonomia, by Tests USD Million (2017-2022)
  • Table 83. Middle East Dysautonomia, by Type USD Million (2017-2022)
  • Table 84. Middle East Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 85. Middle East Dysautonomia, by Tests USD Million (2017-2022)
  • Table 86. Africa Dysautonomia, by Type USD Million (2017-2022)
  • Table 87. Africa Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 88. Africa Dysautonomia, by Tests USD Million (2017-2022)
  • Table 89. North America Dysautonomia, by Country USD Million (2017-2022)
  • Table 90. North America Dysautonomia, by Type USD Million (2017-2022)
  • Table 91. North America Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 92. North America Dysautonomia, by Tests USD Million (2017-2022)
  • Table 93. United States Dysautonomia, by Type USD Million (2017-2022)
  • Table 94. United States Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 95. United States Dysautonomia, by Tests USD Million (2017-2022)
  • Table 96. Canada Dysautonomia, by Type USD Million (2017-2022)
  • Table 97. Canada Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 98. Canada Dysautonomia, by Tests USD Million (2017-2022)
  • Table 99. Mexico Dysautonomia, by Type USD Million (2017-2022)
  • Table 100. Mexico Dysautonomia, by Treatment USD Million (2017-2022)
  • Table 101. Mexico Dysautonomia, by Tests USD Million (2017-2022)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Dysautonomia: by Type(USD Million)
  • Table 113. Dysautonomia Neurocardiogenic Syncope , by Region USD Million (2023-2028)
  • Table 114. Dysautonomia Postural Orthostatic Tachycardia Syndrome , by Region USD Million (2023-2028)
  • Table 115. Dysautonomia Multiple System Atrophy , by Region USD Million (2023-2028)
  • Table 116. Dysautonomia Autonomic Dysreflexia , by Region USD Million (2023-2028)
  • Table 117. Dysautonomia Baroreflex Failure , by Region USD Million (2023-2028)
  • Table 118. Dysautonomia Others , by Region USD Million (2023-2028)
  • Table 119. Dysautonomia: by Treatment(USD Million)
  • Table 120. Dysautonomia Physical Therapy , by Region USD Million (2023-2028)
  • Table 121. Dysautonomia Exercise Therapy , by Region USD Million (2023-2028)
  • Table 122. Dysautonomia Counseling , by Region USD Million (2023-2028)
  • Table 123. Dysautonomia Others , by Region USD Million (2023-2028)
  • Table 124. Dysautonomia: by Tests(USD Million)
  • Table 125. Dysautonomia Cardiovagal and Vasomotor Function Tests , by Region USD Million (2023-2028)
  • Table 126. Dysautonomia Thermoregulatory Sweat Test (TST) , by Region USD Million (2023-2028)
  • Table 127. Dysautonomia Sympathetic Skin Response (SSR) , by Region USD Million (2023-2028)
  • Table 128. Dysautonomia Quantitative Sudomotor Axon Reflex Test , by Region USD Million (2023-2028)
  • Table 129. Dysautonomia Others , by Region USD Million (2023-2028)
  • Table 130. South America Dysautonomia, by Country USD Million (2023-2028)
  • Table 131. South America Dysautonomia, by Type USD Million (2023-2028)
  • Table 132. South America Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 133. South America Dysautonomia, by Tests USD Million (2023-2028)
  • Table 134. Brazil Dysautonomia, by Type USD Million (2023-2028)
  • Table 135. Brazil Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 136. Brazil Dysautonomia, by Tests USD Million (2023-2028)
  • Table 137. Argentina Dysautonomia, by Type USD Million (2023-2028)
  • Table 138. Argentina Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 139. Argentina Dysautonomia, by Tests USD Million (2023-2028)
  • Table 140. Rest of South America Dysautonomia, by Type USD Million (2023-2028)
  • Table 141. Rest of South America Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 142. Rest of South America Dysautonomia, by Tests USD Million (2023-2028)
  • Table 143. Asia Pacific Dysautonomia, by Country USD Million (2023-2028)
  • Table 144. Asia Pacific Dysautonomia, by Type USD Million (2023-2028)
  • Table 145. Asia Pacific Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 146. Asia Pacific Dysautonomia, by Tests USD Million (2023-2028)
  • Table 147. China Dysautonomia, by Type USD Million (2023-2028)
  • Table 148. China Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 149. China Dysautonomia, by Tests USD Million (2023-2028)
  • Table 150. Japan Dysautonomia, by Type USD Million (2023-2028)
  • Table 151. Japan Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 152. Japan Dysautonomia, by Tests USD Million (2023-2028)
  • Table 153. India Dysautonomia, by Type USD Million (2023-2028)
  • Table 154. India Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 155. India Dysautonomia, by Tests USD Million (2023-2028)
  • Table 156. South Korea Dysautonomia, by Type USD Million (2023-2028)
  • Table 157. South Korea Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 158. South Korea Dysautonomia, by Tests USD Million (2023-2028)
  • Table 159. Taiwan Dysautonomia, by Type USD Million (2023-2028)
  • Table 160. Taiwan Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 161. Taiwan Dysautonomia, by Tests USD Million (2023-2028)
  • Table 162. Australia Dysautonomia, by Type USD Million (2023-2028)
  • Table 163. Australia Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 164. Australia Dysautonomia, by Tests USD Million (2023-2028)
  • Table 165. Rest of Asia-Pacific Dysautonomia, by Type USD Million (2023-2028)
  • Table 166. Rest of Asia-Pacific Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 167. Rest of Asia-Pacific Dysautonomia, by Tests USD Million (2023-2028)
  • Table 168. Europe Dysautonomia, by Country USD Million (2023-2028)
  • Table 169. Europe Dysautonomia, by Type USD Million (2023-2028)
  • Table 170. Europe Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 171. Europe Dysautonomia, by Tests USD Million (2023-2028)
  • Table 172. Germany Dysautonomia, by Type USD Million (2023-2028)
  • Table 173. Germany Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 174. Germany Dysautonomia, by Tests USD Million (2023-2028)
  • Table 175. France Dysautonomia, by Type USD Million (2023-2028)
  • Table 176. France Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 177. France Dysautonomia, by Tests USD Million (2023-2028)
  • Table 178. Italy Dysautonomia, by Type USD Million (2023-2028)
  • Table 179. Italy Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 180. Italy Dysautonomia, by Tests USD Million (2023-2028)
  • Table 181. United Kingdom Dysautonomia, by Type USD Million (2023-2028)
  • Table 182. United Kingdom Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 183. United Kingdom Dysautonomia, by Tests USD Million (2023-2028)
  • Table 184. Netherlands Dysautonomia, by Type USD Million (2023-2028)
  • Table 185. Netherlands Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 186. Netherlands Dysautonomia, by Tests USD Million (2023-2028)
  • Table 187. Rest of Europe Dysautonomia, by Type USD Million (2023-2028)
  • Table 188. Rest of Europe Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 189. Rest of Europe Dysautonomia, by Tests USD Million (2023-2028)
  • Table 190. MEA Dysautonomia, by Country USD Million (2023-2028)
  • Table 191. MEA Dysautonomia, by Type USD Million (2023-2028)
  • Table 192. MEA Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 193. MEA Dysautonomia, by Tests USD Million (2023-2028)
  • Table 194. Middle East Dysautonomia, by Type USD Million (2023-2028)
  • Table 195. Middle East Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 196. Middle East Dysautonomia, by Tests USD Million (2023-2028)
  • Table 197. Africa Dysautonomia, by Type USD Million (2023-2028)
  • Table 198. Africa Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 199. Africa Dysautonomia, by Tests USD Million (2023-2028)
  • Table 200. North America Dysautonomia, by Country USD Million (2023-2028)
  • Table 201. North America Dysautonomia, by Type USD Million (2023-2028)
  • Table 202. North America Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 203. North America Dysautonomia, by Tests USD Million (2023-2028)
  • Table 204. United States Dysautonomia, by Type USD Million (2023-2028)
  • Table 205. United States Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 206. United States Dysautonomia, by Tests USD Million (2023-2028)
  • Table 207. Canada Dysautonomia, by Type USD Million (2023-2028)
  • Table 208. Canada Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 209. Canada Dysautonomia, by Tests USD Million (2023-2028)
  • Table 210. Mexico Dysautonomia, by Type USD Million (2023-2028)
  • Table 211. Mexico Dysautonomia, by Treatment USD Million (2023-2028)
  • Table 212. Mexico Dysautonomia, by Tests USD Million (2023-2028)
  • Table 213. Research Programs/Design for This Report
  • Table 214. Key Data Information from Secondary Sources
  • Table 215. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dysautonomia: by Type USD Million (2017-2022)
  • Figure 5. Global Dysautonomia: by Treatment USD Million (2017-2022)
  • Figure 6. Global Dysautonomia: by Tests USD Million (2017-2022)
  • Figure 7. South America Dysautonomia Share (%), by Country
  • Figure 8. Asia Pacific Dysautonomia Share (%), by Country
  • Figure 9. Europe Dysautonomia Share (%), by Country
  • Figure 10. MEA Dysautonomia Share (%), by Country
  • Figure 11. North America Dysautonomia Share (%), by Country
  • Figure 12. Global Dysautonomia share by Players 2022 (%)
  • Figure 13. Global Dysautonomia share by Players (Top 3) 2022(%)
  • Figure 14. Global Dysautonomia share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Novartis Pharmaceuticals Corporation (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Novartis Pharmaceuticals Corporation (Switzerland) Revenue: by Geography 2022
  • Figure 18. Corlanor (Amgen Inc.) (United States) Revenue, Net Income and Gross profit
  • Figure 19. Corlanor (Amgen Inc.) (United States) Revenue: by Geography 2022
  • Figure 20. NORTHERA (Lundbeck NA Ltd.) (United States) Revenue, Net Income and Gross profit
  • Figure 21. NORTHERA (Lundbeck NA Ltd.) (United States) Revenue: by Geography 2022
  • Figure 22. Teva Cares Foundation (Teva Pharmaceutical Industries, Ltd) (United States) Revenue, Net Income and Gross profit
  • Figure 23. Teva Cares Foundation (Teva Pharmaceutical Industries, Ltd) (United States) Revenue: by Geography 2022
  • Figure 24. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 26. Celltex Therapeutics Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Celltex Therapeutics Corporation (United States) Revenue: by Geography 2022
  • Figure 28. Merck Sharp & Dohme Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Merck Sharp & Dohme Corp. (United States) Revenue: by Geography 2022
  • Figure 30. Theravance Biopharma (United States) Revenue, Net Income and Gross profit
  • Figure 31. Theravance Biopharma (United States) Revenue: by Geography 2022
  • Figure 32. Shire Development, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Shire Development, Inc. (United States) Revenue: by Geography 2022
  • Figure 34. H. Lundbeck A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 35. H. Lundbeck A/S (Denmark) Revenue: by Geography 2022
  • Figure 36. Global Dysautonomia: by Type USD Million (2023-2028)
  • Figure 37. Global Dysautonomia: by Treatment USD Million (2023-2028)
  • Figure 38. Global Dysautonomia: by Tests USD Million (2023-2028)
  • Figure 39. South America Dysautonomia Share (%), by Country
  • Figure 40. Asia Pacific Dysautonomia Share (%), by Country
  • Figure 41. Europe Dysautonomia Share (%), by Country
  • Figure 42. MEA Dysautonomia Share (%), by Country
  • Figure 43. North America Dysautonomia Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis Pharmaceuticals Corporation (Switzerland)
  • Corlanor (Amgen Inc.) (United States)
  • NORTHERA (Lundbeck NA Ltd.) (United States)
  • Teva Cares Foundation (Teva Pharmaceutical Industries, Ltd) (United States)
  • Pfizer Inc. (United States)
  • Celltex Therapeutics Corporation (United States)
  • Merck Sharp & Dohme Corp. (United States)
  • Theravance Biopharma (United States)
  • Shire Development, Inc. (United States)
  • H. Lundbeck A/S (Denmark)
Additional players considered in the study are as follows:
Axsome Therapeutics, Inc. (United States) , Medtronic (Dublin, Ireland) , Biotronik (Germany) , Nfocus Neuro (United States) , Cala Health (United States)
Select User Access Type

Key Highlights of Report


Dec 2023 203 Pages 95 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dysautonomia Market Quantitative research analysis
Global Dysautonomia Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Novartis Pharmaceuticals Corporation (Switzerland), Corlanor (Amgen Inc.) (United States), NORTHERA (Lundbeck NA Ltd.) (United States), Teva Cares Foundation (Teva Pharmaceutical Industries, Ltd) (United States), Pfizer Inc. (United States), Celltex Therapeutics Corporation (United States), Merck Sharp & Dohme Corp. (United States), Theravance Biopharma (United States), Shire Development, Inc. (United States) and H. Lundbeck A/S (Denmark) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Exercises and Counseling Related Treatment for Dysautonomia " is seen as one of major influencing trends for Dysautonomia Market during projected period 2022-2028.
The Dysautonomia market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Dysautonomia Market Report?

Have a Query? Click Here

Other Related Reports

Coronavirus Comprehensive Study by Type (Middle East Respiratory Syndrome (MERS) {MER-CoV}, Severe Acute Respiratory Syndrome (SARS) {SAR-CoV}), Application (Hospitals, Research Laboratories, Clinics...
$ 3650
Hunter Syndrome Treatment Comprehensive Study by Type (Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), Others), End-user (Life Science Companies, Research Institutes, Hos...
$ 3500
Acute Wound Care Comprehensive Study by Type (Infection Management, Exudate Management,, Active Wound Care, Therapy Devices), Wounds (Surgical Wounds, Traumatic Wounds), End-user (Long- Term Care Fac...
$ 3450
Vascular Injury Treatment Comprehensive Study by Type (Lateral Arteriorrhaphy/Venorrhaphy, Patch Angioplasty, Bypass Graft, Extraanatomic Bypass, Thrombectomy, Others), Application (Hospitals, Clinic...
$ 3650
Batten Disease Treatment Comprehensive Study by Disease Type (Juvenile NCL, Infantile NCL, Late infantile NCL, Adult NCL), Route of Administration (Oral, Parenteral), Therapy Type (Occupational Thera...
$ 3450
Food Allergy Diagnosis Comprehensive Study by Type (Diagnostic Products (Instruments, Consumables, Services, Tests Type), Therapeutic Treatment Type (Antihistamines, Epinephrine auto-injector)), Appl...
$ 3750